TAIPEI, Taiwan Jul. 10, 2024 – ImmunAdd won the Startup of the Year at the 2024 Taiwan BIO Awards and the Awards ceremony will be held on July 25th. ImmunAdd is a biotech pharmaceutical research and development company focused on drug design and formulation development. ImmunAdd was founded in 2022 but has put efforts into […]
TAIPEI, Taiwan Jul 5, 2024 – Taiwan Intellectual Property Office has granted ImmunAdd the patent on the preparation of triterpenoid compound. “Innovation for Better Health” We are ImmunAdd.
TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, attended to WVC Washington during 4/2~4/4. ImmunAdd is a group of scientists with extensive knowledge of medical chemistry, drug formulation, drug regulations, biological animal evaluation, and clinical trials, and is working on developing drugs for infectious disease, […]
TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, attends BIO International Convention during 6/3~6/6 and will be in Taiwan Pavilon (Booth: 1917). ImmunAdd developed a synthetic saponin IA-05 which can be synthesized in large scale and manufactured in GMP facility. IA-05 is formulated in aqueous […]
TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, proudly announced that our funder and CEO, Dr. Pi-Hui Liang, awarded “Outstanding Research Award”. Dr. Pi-Hui Liang leads her team, leaning on their erudite knowledge in medical chemistry, drug formulation, and regulations, to work on developing therapies […]
TAIPEI, Taiwan Jan 18, 2024 – IP Australia has granted ImmunAdd the patent on the synthetic saponin molecules. Innovation for Better Health We are ImmunAdd.
TAIPEI, Taiwan Jan 13, 2024 – Canadian Intellectual Property Office has granted ImmunAdd the patent on the synthetic saponin molecules. “Innovation for Better Health” We are ImmunAdd.
ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13. Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a poster […]
ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the BIO International Convention conference in San Diego, California, on June 13-16. Founder of ImmunAdd, Pi-Hui Liang, said, “My team and I are delighted to attend the BIO conference in San Diego, where we will show our […]
TAIPEI, Taiwan Jun 28, 2022 – Taiwan Intellectual Property Office has granted ImmunAdd the patent on the synthetic saponin molecules. Innovation for Better Health We are ImmunAdd.
- 1
- 2